Your session is about to expire
← Back to Search
Anifrolumab for Hidradenitis Suppurativa
Study Summary
This trial aims to see if a drug called anifrolumab can effectively treat Hidradenitis Suppurativa (HS) and improve quality of life for patients. Anifrolum
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 373 Patients • NCT02446899Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are patients currently able to enroll in this ongoing study?
"As per the details on clinicaltrials.gov, this particular research project is not currently enrolling new participants. The trial's initial posting was on June 1st, 2024, and its most recent update occurred on April 15th of the same year. Although recruitment for this specific study has concluded, there are numerous other trials actively seeking patient participation - a total of 43 studies are open for enrollment at present."
Has Anifrolumab received official authorization from the FDA?
"The safety assessment for Anifrolumab received a score of 2 from our team at Power, as this is a Phase 2 trial where some safety data exists but efficacy data is lacking."
Share this study with friends
Copy Link
Messenger